References
- Baber RJ, Panay N, Fenton A. IMS recommendations on women's midlife health and menopause. Climacteric. 2016;19:109–150.
- Cox L, Liu JH. Primary ovarian insufficiency: an update. Int J Women Health. 2014;6:235–243.
- Vujovic S, Brincat M, Erel T, et al. EMAS position statement: managing women with premature ovarian failure. Maturitas. 2010;67:91–93.
- Panay N, Fenton A. Premature ovarian failure: a growing concern. Climacteric. 2008;11:1–3.
- Caroppo E, D’Amato G. Resumption of ovarian function after 4 years of estro-progestin treatment in a young woman with Crohn's disease and premature ovarian insufficiency: a case report. J Assist Reprod Genet. 2012;29:973–977.
- Gleicher N, Barad D. Dehydroepiandrosteron supplementation in diminshed ovarian reserve. Reprod Biol Endocrinol. 2011;9:67–76.
- Dragojevic Dikic S, Jovanovic AM, Dikic S, et al. Melatonin: a “Higgs boson” in human reproduction. Gynecol Endocrinol. 2015;31:92–101.
- Kokcu A. Premature ovarian failure from current perspective. Gynecol Endocrinol. 2010;26:555–562.
- Vujović S, Ivovic M, Tančić-Gajić M, et al. Endometrium receptivity in premature ovarian insufficiency – how to improve fertility rate and predict disease? Gynecol Endocrinol. 2018;34:1011–1015.
- Dragojević Dikić S, Rakić S, Nikolić B, et al. Hormone replacement therapy and successful pregnancy in a patient with premature ovarian failure. Gynecol Endocrinol. 2009;25:769–772.
- Artini PG, Pinelli S, Papini F, et al. Supplementation with dehydroepiandrosterone as a promising treatment for poor responders. J Fertiliz in Vitro. 2011;1:1–5.
- Genazzani AR, Pluchino N. DHEA therapy in postmenopausal women: the need to move forward beyond the lack of evidence. Climacteric. 2010;13:314–316.
- Brzezinski A. Melatonin in humans. N Engl J Med. 1997;336:186–195.
- Carlomagno G, Minini M, Tilotta M, et al. From implantation to birth: insight into molecular melatonin functions. Int J Mol Sci. 2018;19:2802–2818.
- Reiter RJ, Rosales-Corral SA, Manchester LC, et al. Peripheral reproductive organ health and melatonin: ready for prime time. Int J Mol Sci. 2013;14:7231–7272.
- Li Y, Liu H, Sun J, et al. Effect of melatonin on the peripheral T lymphocyte cell cycle and levels of reactive oxygen species in patients with premature ovarian failure. Exp Ther Med. 2016;12:3589–3594.
- Dragojević-Dikić S, Marisavljević D, Mitrović A, et al. An immunological insight into premature ovarian failure (POF). Autoimmunity Rev. 2010;9:771–774.
- Luborsky J, Llanes B, Davies S, et al. Ovarian autoimmunity: greater frequency of autoantibodies in premature menopause and unexplained infertility than in general population. Clin Immunol. 1999;90:368–374.
- Hatirnaz S, Basbug A, Akarsu S, et al. Outcomes of random start versus clomiphene citrate and gonadotropin cycles in occult premature ovarian insufficiency patients, refusing oocyte donation: a retrospective cohort study. Gynecol Endocrinol. 2018;34:949–954.
- van Karseren YM, Schoemaker J. Premature ovarian failure: a systematic review on therapeutic interventions restore ovarian function and achieve pregnancy. Hum Reprod Update. 1999;5:483–492.
- Kalu E, Panay N. Spontaneous premature ovarian failure: management challenges. Gynecol Endocrinol. 2008;24:273–279.
- Barad D, Gleicher N. Effect of dehydroepiandrosterone on oocyte and embryo yields, embryo grade and cell number in IVF. Hum Reprod. 2006;21:2845–2849.
- Reiter RJ, Mayo JC, Tan D-X, et al. Melatonin as an antioxidant: under promises but over delivers. J Pineal Res. 2016;61:253–278.
- Tamura H, Takasaki A, Miwa I, et al. Oxidative stress impairs oocyte quality and melatonin protects oocytes from free radical damage and improves fertilization rate. J Pineal Res. 2008;44:280–287.
- Ma M, Chen X-Y, Li B, et al. melatonin protects premature ovarian insufficiency induced by tripterygium glycosides: role of SIRT1. Am J Transl Res. 2017;9:1580–1602.